NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology
20 juil. 2021 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® device has received Breakthrough Designation from the U.S. Food and Drug...
NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call
15 juil. 2021 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on...
NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial
15 juin 2021 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to...
NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences
09 juin 2021 08h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will...
NeuroMetrix Reports Q1 2021 Financial Results
22 avr. 2021 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in...
NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
15 avr. 2021 13h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on...
NeuroMetrix Reports Q4 and Full Year 2020 Financial Results
28 janv. 2021 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is...
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call
22 janv. 2021 11h05 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of...
NeuroMetrix Reports Q3 2020 Financial Results
22 oct. 2020 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading...
NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call
15 oct. 2020 11h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on...